Mineralys Therapeutics Stock (NASDAQ:MLYS)
Previous Close
$23.76
52W Range
$12.59 - $47.65
50D Avg
$27.92
200D Avg
$32.94
Market Cap
$1.59B
Avg Vol (3M)
$1.46M
Beta
0.56
Div Yield
-
MLYS Company Profile
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
MLYS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IDYA | IDEAYA Biosciences, Inc. |
| ADPT | Adaptive Biotechnologies Corporation |
| RXRX | Recursion Pharmaceuticals, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| CPRX | Catalyst Pharmaceuticals, Inc. |
| BEAM | Beam Therapeutics Inc. |
| CDTX | Cidara Therapeutics, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| ZLAB | Zai Lab Limited |
| SRRK | Scholar Rock Holding Corporation |